Despite recent advances in modern medicine, hundreds of millions of people are affected by acute and chronic diseases with limited or no known treatment options. Kymera Therapeutics is pioneering a game-changing new therapeutic modality and platform with the potential to transform drug discovery and deliver breakthrough medicines for previously untreatable diseases.

REVOLUTIONARY SCIENCE

HARNESSING THE POWER OF TARGETED PROTEIN DEGRADATION

Hetero Bifunctional ProcessNobel Prize winning scientists have identified an important cellular process responsible for recycling proteins in the body. Kymera is unlocking that system, accessing novel biology to target and degrade disease-causing proteins and treat previously undruggable diseases.

Kymera’s breakthrough therapeutics hijack and redirect the ubiquitin proteosome system (UPS), central to the regulation of cellular processes and the molecular biology of protein degradation. Using a small molecule-based knockdown strategy, we rationally design and develop heterobifunctional molecules or chimeras. These molecules recruit otherwise intractable disease-causing proteins to E3 ubiquitin ligases, resulting in the protein’s ubiquitination and subsequent degradation.

Learn more about targeted protein degradation

PIONEERING TECHNOLOGY

PEGASUS™

We understand the urgency of our endeavor. Kymera has assembled a world-class team of drug hunters to build a powerful targeted protein degradation platform and drug discovery engine. Pegasus™ was engineered to overcome the unique challenges of targeted protein degradation and accelerate drug discovery and development with an unmatched ability to identify, target and degrade the most intractable of proteins.

Learn More About Our Pegasus™ PLATFORM.

Leadership Team

Laurent Audoly, PhD
Chief Executive Officer
Read Bio
X

Laurent joined Kymera Therapeutics from Pierre Fabre, where he was the Global Head of R&D and a managing partner at the PF fund for innovation. Laurent started his drug development career at Pfizer, where he led multiple discovery efforts in inflammation and immunology contributing to the identification of Xeljanz®. Subsequently, he held various strategic, leadership and operational roles at MedImmune, Merck, and Pieris, building global collaborations and therapeutic pipeline value across oncology, autoimmunity, respiratory, neuropsychiatry, dermatology, cardiovascular and metabolic diseases, contributing to the launch of multiple products currently on the market. He earned his PhD in Pharmacology from Vanderbilt and was an American Heart Association postdoctoral fellow at Duke University. Laurent has authored >70 patents and papers published in top-tier scientific journals including J Exp Med, Nature Immunology, Nature Medicine, Nature Neuroscience, and PNAS. Laurent is a co-author on more than 70 peer-reviewed publications and patents and has served on various NIH study sections. He serves as a board member and advisor for multiple healthcare organizations worldwide to help accelerate the discovery and advancement of novel therapies for patients and their families.

Nello Mainolfi, PhD
Founder and Chief Technology Officer
Read Bio
X

Before founding Kymera, Nello was head of drug discovery at Raze Therapeutics (an Atlas portfolio company) where he helped develop first in class molecules against novel cancer metabolism targets with implications in both oncology and immuno-metabolism. Nello started his drug discovery career in the global discovery chemistry group at the Novartis Institutes for Biomedical Research, where he contributed and in most cases led teams to the identification of more than 10 compounds that have entered preclinical and clinical development across a series of disease areas. Notably first in class small molecules inhibitors of several complement proteins for inflammation and ocular diseases. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver multiple development candidates. Nello has authored >40 papers and patents and has written reviews in the areas of medicinal chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

Mark E. Nuttall, PhD
Chief Business Officer
Read Bio
X

Mark has extensive experience in the biopharmaceutical industry, leading Business Development in multiple disease franchises and executing a range of deal types. Prior to joining Kymera, he was Head of Immunology and Neuroscience Licensing and Business Development at Sanofi Genzyme. He also previously led global strategy and transactions for Neuroscience BD at J&J and worked at GlaxoSmithKline in Discovery Research, Project Management and Business Development.

Mark completed post-doctoral studies at AstraZeneca and Penn State University. He holds a B.Sc (Hons.) from University College Cardiff, Wales and a Ph.D. from the University of Aberdeen, Scotland. Mark has served on academic and industrial scientific advisory boards and published 50 scientific papers on musculoskeletal and metabolic diseases.

Jared Gollob, MD
Chief Medical Officer
Read Bio
X

In his role as CMO, Jared leads clinical development for Kymera Therapeutics, advancing clinical candidates identified by Kymera’s proprietary Pegasus™ targeted protein degradation platform. Jared joined Kymera from Alnylam Pharmaceuticals, where he was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis. There, he led early and late stage clinical programs in infectious disease, oncology, and amyloidosis that provided the first proof of concept in humans for RNA interference therapeutics and culminated in the FDA and EMA approvals of ONPATTROTM for the treatment of hereditary transthyretin amyloidosis. Jared previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. He has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. Jared received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.

X

Laurent joined Kymera Therapeutics from Pierre Fabre, where he was the Global Head of R&D and a managing partner at the PF fund for innovation. Laurent started his drug development career at Pfizer, where he led multiple discovery efforts in inflammation and immunology contributing to the identification of Xeljanz®. Subsequently, he held various strategic, leadership and operational roles at MedImmune, Merck, and Pieris, building global collaborations and therapeutic pipeline value across oncology, autoimmunity, respiratory, neuropsychiatry, dermatology, cardiovascular and metabolic diseases, contributing to the launch of multiple products currently on the market. He earned his PhD in Pharmacology from Vanderbilt and was an American Heart Association postdoctoral fellow at Duke University. Laurent has authored >70 patents and papers published in top-tier scientific journals including J Exp Med, Nature Immunology, Nature Medicine, Nature Neuroscience, and PNAS. Laurent is a co-author on more than 70 peer-reviewed publications and patents and has served on various NIH study sections. He serves as a board member and advisor for multiple healthcare organizations worldwide to help accelerate the discovery and advancement of novel therapies for patients and their families.

Before founding Kymera, Nello was head of drug discovery at Raze Therapeutics (an Atlas portfolio company) where he helped develop first in class molecules against novel cancer metabolism targets with implications in both oncology and immuno-metabolism. Nello started his drug discovery career in the global discovery chemistry group at the Novartis Institutes for Biomedical Research, where he contributed and in most cases led teams to the identification of more than 10 compounds that have entered preclinical and clinical development across a series of disease areas. Notably first in class small molecules inhibitors of several complement proteins for inflammation and ocular diseases. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver multiple development candidates. Nello has authored >40 papers and patents and has written reviews in the areas of medicinal chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

Mark has extensive experience in the biopharmaceutical industry, leading Business Development in multiple disease franchises and executing a range of deal types. Prior to joining Kymera, he was Head of Immunology and Neuroscience Licensing and Business Development at Sanofi Genzyme. He also previously led global strategy and transactions for Neuroscience BD at J&J and worked at GlaxoSmithKline in Discovery Research, Project Management and Business Development.

Mark completed post-doctoral studies at AstraZeneca and Penn State University. He holds a B.Sc (Hons.) from University College Cardiff, Wales and a Ph.D. from the University of Aberdeen, Scotland. Mark has served on academic and industrial scientific advisory boards and published 50 scientific papers on musculoskeletal and metabolic diseases.

In his role as CMO, Jared leads clinical development for Kymera Therapeutics, advancing clinical candidates identified by Kymera’s proprietary Pegasus™ targeted protein degradation platform. Jared joined Kymera from Alnylam Pharmaceuticals, where he was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis. There, he led early and late stage clinical programs in infectious disease, oncology, and amyloidosis that provided the first proof of concept in humans for RNA interference therapeutics and culminated in the FDA and EMA approvals of ONPATTROTM for the treatment of hereditary transthyretin amyloidosis. Jared previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. He has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. Jared received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.

Board of Directors

Laurent Audoly, PhD
Read Bio
X

Laurent has led pharma and biotech R&D organizations in the U.S. and EU for more than 20 years, discovering and developing novel medicines, including five approved drugs (both small and large molecule) in inflammation, dermatology, cardiovascular diseases, and oncology. Prior to joining Kymera, Laurent was the head of R&D at Pierre Fabre, an EU-based pharmaceutical company with more than $2.5B in revenues. During his tenure there, he championed the in- and out-licensing of numerous clinical-stage assets and technologies, and directly contributed to IND entries and POC and LCM studies in oncology, dermatology, and neuropsychiatry. He has also held leadership positions at Pfizer, Merck, MedImmune and Pieris.

Laurent earned his PhD in pharmacology at Vanderbilt University, and did his post-doctoral training at Duke University where he was awarded a fellowship from the American Heart Association. Laurent is a co-author on more than 70 peer-reviewed publications and patents and has served on various NIH study sections. He serves as a board member and advisor for multiple healthcare organizations worldwide to help accelerate the discovery and advancement of novel therapies for patients and their families.

Bruce Booth, DPhil
Chairman
Read Bio
X

Bruce is a partner at Atlas Venture where he focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. He is currently chairman AvroBio, mirage Therapeutics, Nimbus Therapeutics, Rodin Therapeutics and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapeutics, Unum Therapeutics, and Zafgen. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail) and Stromedix (acquired by Biogen). Bruce also serves as an advisor in various capacities to UCB, Shire, Pfizer and Takeda, and is on the board of the National Venture Capital Association. As a British Marshall Scholar, Bruce received a DPhil in molecule immunology from Oxford University and a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Steve Hall, PhD
Read Bio
X

Steve is a General Partner at Lilly Ventures and has more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations. Prior to joining Lilly Ventures, Steve was SVP of R&D at Serenex, Inc., where he was also a co-founder. He also has held operational and leadership roles at Eli Lilly, Sphinx Pharmaceuticals, and Bristol-Myers Squibb in the areas of oncology, cardiovascular disease, and lead generation technologies. Steve currently sits on the boards of Cavio Pharma, Esanex, FORMA Therapeutics, Hydra Biosciences, Lysosomal Therapeutics and Nimbus Therapeutics. Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his PhD in organic chemistry from Massachusetts Institute of Technology.

Joanna Horobin, MB, ChB
Read Bio
X

Joanna Horobin, M.B., Ch.B, is Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc.  Prior to joining Idera in November 2015, Dr. Horobin was most recently the Chief Medical Officer of Verastem, Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals.  Additionally, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the launch of the global Oncology business unit which included the commercial introduction of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer.  Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim).  Prior, Dr. Horobin played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® and Relafen®/Reliflex®.

Dr. Horobin currently serves as a Non-Executive Director of Nordic Nanovector ASA. Dr. Horobin received her medical degree from the University of Manchester, United Kingdom.

Donald W. Nicholson, PhD
Read Bio
X

Dr. Don Nicholson is the former Chief Executive Officer of Nimbus Therapeutics. He joined from Merck, where he held various strategic, leadership and operational roles in diverse therapeutic areas, including respiratory, inflammation, immunology, bone, endocrine, urology, infectious disease and neurosciences. He began his career in 1998 at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility including Vice President & Site Head of the Merck Neurosciences Research site in San Diego, and most recently as Vice President and Worldwide Discovery Head for the Respiratory & Immunology Franchise, based in Kenilworth, N.J. Don has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally recognized for his contributions to the field of apoptotic cell death. He received his Ph.D. and an Honors B.Sc. degree in Biochemistry from the University of Western Ontario, and trained as a Medical Research Council postdoctoral fellow at the University of Munich in Germany. He is the recipient of multiple academic and professional honors.

X

Laurent has led pharma and biotech R&D organizations in the U.S. and EU for more than 20 years, discovering and developing novel medicines, including five approved drugs (both small and large molecule) in inflammation, dermatology, cardiovascular diseases, and oncology. Prior to joining Kymera, Laurent was the head of R&D at Pierre Fabre, an EU-based pharmaceutical company with more than $2.5B in revenues. During his tenure there, he championed the in- and out-licensing of numerous clinical-stage assets and technologies, and directly contributed to IND entries and POC and LCM studies in oncology, dermatology, and neuropsychiatry. He has also held leadership positions at Pfizer, Merck, MedImmune and Pieris.

Laurent earned his PhD in pharmacology at Vanderbilt University, and did his post-doctoral training at Duke University where he was awarded a fellowship from the American Heart Association. Laurent is a co-author on more than 70 peer-reviewed publications and patents and has served on various NIH study sections. He serves as a board member and advisor for multiple healthcare organizations worldwide to help accelerate the discovery and advancement of novel therapies for patients and their families.

Bruce is a partner at Atlas Venture where he focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. He is currently chairman AvroBio, mirage Therapeutics, Nimbus Therapeutics, Rodin Therapeutics and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapeutics, Unum Therapeutics, and Zafgen. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail) and Stromedix (acquired by Biogen). Bruce also serves as an advisor in various capacities to UCB, Shire, Pfizer and Takeda, and is on the board of the National Venture Capital Association. As a British Marshall Scholar, Bruce received a DPhil in molecule immunology from Oxford University and a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Steve is a General Partner at Lilly Ventures and has more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations. Prior to joining Lilly Ventures, Steve was SVP of R&D at Serenex, Inc., where he was also a co-founder. He also has held operational and leadership roles at Eli Lilly, Sphinx Pharmaceuticals, and Bristol-Myers Squibb in the areas of oncology, cardiovascular disease, and lead generation technologies. Steve currently sits on the boards of Cavio Pharma, Esanex, FORMA Therapeutics, Hydra Biosciences, Lysosomal Therapeutics and Nimbus Therapeutics. Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his PhD in organic chemistry from Massachusetts Institute of Technology.

Joanna Horobin, M.B., Ch.B, is Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc.  Prior to joining Idera in November 2015, Dr. Horobin was most recently the Chief Medical Officer of Verastem, Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals.  Additionally, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the launch of the global Oncology business unit which included the commercial introduction of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer.  Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim).  Prior, Dr. Horobin played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® and Relafen®/Reliflex®.

Dr. Horobin currently serves as a Non-Executive Director of Nordic Nanovector ASA. Dr. Horobin received her medical degree from the University of Manchester, United Kingdom.

Dr. Don Nicholson is the former Chief Executive Officer of Nimbus Therapeutics. He joined from Merck, where he held various strategic, leadership and operational roles in diverse therapeutic areas, including respiratory, inflammation, immunology, bone, endocrine, urology, infectious disease and neurosciences. He began his career in 1998 at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility including Vice President & Site Head of the Merck Neurosciences Research site in San Diego, and most recently as Vice President and Worldwide Discovery Head for the Respiratory & Immunology Franchise, based in Kenilworth, N.J. Don has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally recognized for his contributions to the field of apoptotic cell death. He received his Ph.D. and an Honors B.Sc. degree in Biochemistry from the University of Western Ontario, and trained as a Medical Research Council postdoctoral fellow at the University of Munich in Germany. He is the recipient of multiple academic and professional honors.

Scientific Advisors

David Spiegel, MD, PhD
Professor of Chemistry, Yale University
Steven A. Carr, PhD
Senior Director of Proteomics, Broad Institute
Ning Zheng, PhD
Professor of Pharmacology, University of Washington and Investigator, Howard Hughes Medical Institute
Jean-Laurent Casanova, MD, PhD
Professor, Rockefeller University and Investigator, Howard Hughes Medical Institute
David Frank, MD, PhD
Associate Professor, Oncology, Dana-Farber Cancer Institute
Michele Pagano, MD
Chair, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine and Investigator, Howard Hughes Medical Institute
Nick Keen, PhD
Chief Scientific Officer, Bicycle Therapeutics
Owen O’Connor, MD, PhD
American Cancer Society Professor and Director of the Center for Lymphoid Malignancies, Columbia University
Antonio Sica, PhD
Professor of General Pathology, Humanitas Clinical and Research Center
Robert Terkeltaub, MD
Professor, Rheumatology, University of California San Diego

Careers

Are you interested in working with Kymera Therapeutics?

Join us in defying convention, and delivering bold new therapies for patients.

See our current list of openings or email us at careers@kymeratx.com to tell us why you think you’d be a good fit.